Scott joins Neurotech with a demonstrated track record in global rare and specialty eyecare experience. He most recently worked at Novartis where he was the Global Marketing Head for Luxturna (voretigene neparvovec-rzyl), responsible for advancing the global strategy for the first commercially approved ocular gene therapy. Before Novartis, Scott was at Shire, where he was instrumental in the build-out of the U.S. ophthalmics franchise and launch of Xiidra, culminating in the divestiture to Novartis for up to $5.3 billion. Prior he spent 12 years at Bausch & Lomb, where he held roles of increasing responsibility across research and development (R&D) and marketing.
Scott earned his M.S. in Pharmacoeconomics from the University of Florida and his M.B.A. from the University of Tampa after completing his B.S. in Biology at the University of South Florida.
,